Literature DB >> 33451933

Corrigendum to "Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy" [Neuromuscular Disorders, Vol. 30 (6) 2020, 492-502].

Kathryn R Wagner1, Hoda Z Abdel-Hamid2, Jean K Mah3, Craig Campbell4, Michela Guglieri5, Francesco Muntoni6, Yasuhiro Takeshima7, Craig M McDonald8, Anna Kostera-Pruszczyk9, Peter Karachunski10, Russell J Butterfield11, Eugenio Mercuri12, Chiara Fiorillo13, Enrico S Bertini14, Cuixia Tian15, Jeffery Statland16, Alesia B Sadosky17, Vivek S Purohit18, Sarah P Sherlock18, Jeffrey P Palmer18, Michael Binks18, Lawrence Charnas18, Shannon Marraffino18, Brenda L Wong19.   

Abstract

Entities:  

Year:  2021        PMID： 33451933     DOI： 10.1016/j.nmd.2021.01.001

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN： 0960-8966            Impact factor:   4.296


× No keyword cloud information.
  4 in total

Review 1.  Inhibition of myostatin and related signaling pathways for the treatment of muscle atrophy in motor neuron diseases.

Authors:  Elena Abati; Arianna Manini; Giacomo Pietro Comi; Stefania Corti
Journal:  Cell Mol Life Sci       Date:  2022-06-21       Impact factor: 9.207

Review 2.  Myostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs.

Authors:  Buel D Rodgers; Christopher W Ward
Journal:  Endocr Rev       Date:  2022-03-09       Impact factor: 25.261

Review 3.  Targeting the myostatin signaling pathway to treat muscle loss and metabolic dysfunction.

Authors:  Se-Jin Lee
Journal:  J Clin Invest       Date:  2021-05-03       Impact factor: 14.808

4.  Quantitative muscle MRI biomarkers in Duchenne muscular dystrophy: cross-sectional correlations with age and functional tests.

Authors:  Sarah P Sherlock; Yao Zhang; Michael Binks; Shannon Marraffino
Journal:  Biomark Med       Date:  2021-06-22       Impact factor: 2.851
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.